From: BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
N with correct classification
BRCA1-like classification
BRCA1-mutated
88% (14/16)
BRCA1 promoter methylation
96% (26/27)
BRCA2-like classification
BRCA2-mutated
93% (13/14)